169 related articles for article (PubMed ID: 24403498)
1. Targeted agents and oxaliplatin-containing regimens for the treatment of colon cancer.
Bonetti A; Giuliani J; Muggia F
Anticancer Res; 2014 Jan; 34(1):423-34. PubMed ID: 24403498
[TBL] [Abstract][Full Text] [Related]
2. Why do targeted agents not work in the adjuvant setting in colon cancer?
Oyan B
Expert Rev Anticancer Ther; 2012 Oct; 12(10):1337-45. PubMed ID: 23176621
[TBL] [Abstract][Full Text] [Related]
3. [Treatment of advanced and/or metastatic colorectal cancer with bevacizumab in combination with oxaliplatin-based chemotherapy (Folfox7 regimen)].
Oukkal M; Djilat K; Hadjam RM; Mahgoun M; Bentabak K; Graba A; Smail N; Kaci NA; Ahmed RB; Bouzid K
Bull Cancer; 2010 Apr; 97(4):469-74. PubMed ID: 20385517
[TBL] [Abstract][Full Text] [Related]
4. Targeted agents for adjuvant therapy of colon cancer.
Saif MW
Clin Colorectal Cancer; 2006 May; 6(1):46-51. PubMed ID: 16796791
[TBL] [Abstract][Full Text] [Related]
5. Adaptation of international guidelines for metastatic colorectal cancer: an asian consensus.
Cheng AL; Li J; Vaid AK; Ma BB; Teh C; Ahn JB; Bello M; Charoentum C; Chen LT; de Lima Lopes G; Ho GF; Kong HL; Lam KO; Liu TS; Park YS; Sriuranpong V; Sudoyo AW; Wang JY; Zhang J; Zhang SZ; Ciardiello F; Köhne CH; Shaw M; Kim TW
Clin Colorectal Cancer; 2014 Sep; 13(3):145-55. PubMed ID: 25209093
[TBL] [Abstract][Full Text] [Related]
6. Chemotherapy of metastatic colorectal cancer.
Prescrire Int; 2010 Oct; 19(109):219-24. PubMed ID: 21180382
[TBL] [Abstract][Full Text] [Related]
7. [Recent results of irinotecan therapy in colorectal cancer].
Láng I; Hitre E
Magy Onkol; 2004; 48(4):281-8. PubMed ID: 15655572
[TBL] [Abstract][Full Text] [Related]
8. [Adjuvant and palliative anticancer treatment of colon carcinoma in 2004].
Medinger M; Steinbild S; Mross K
Praxis (Bern 1994); 2004 Sep; 93(40):1633-44. PubMed ID: 15495753
[TBL] [Abstract][Full Text] [Related]
9. Integration of novel agents in the treatment of colorectal cancer.
Iqbal S; Lenz HJ
Cancer Chemother Pharmacol; 2004 Sep; 54 Suppl 1():S32-9. PubMed ID: 15309512
[TBL] [Abstract][Full Text] [Related]
10. Cetuximab-based or bevacizumab-based first-line treatment in patients with KRAS p.G13D-mutated metastatic colorectal cancer: a pooled analysis.
Modest DP; Reinacher-Schick A; Stintzing S; Giessen C; Tannapfel A; Laubender RP; Brodowicz T; Knittelfelder R; Vrbanec D; Schmiegel W; Heinemann V; Zielinski CC
Anticancer Drugs; 2012 Jul; 23(6):666-73. PubMed ID: 22441566
[TBL] [Abstract][Full Text] [Related]
11. Predictive and prognostic factors in the complex treatment of patients with colorectal cancer.
László L
Magy Onkol; 2010 Dec; 54(4):383-94. PubMed ID: 21163770
[TBL] [Abstract][Full Text] [Related]
12. [The development of the first line treatment of metastatic colorectal cancer (mCRC)].
Landherr L; Nagykálnai T
Magy Onkol; 2009 Sep; 53(3):237-46. PubMed ID: 19793687
[TBL] [Abstract][Full Text] [Related]
13. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer.
Hecht JR; Mitchell E; Chidiac T; Scroggin C; Hagenstad C; Spigel D; Marshall J; Cohn A; McCollum D; Stella P; Deeter R; Shahin S; Amado RG
J Clin Oncol; 2009 Feb; 27(5):672-80. PubMed ID: 19114685
[TBL] [Abstract][Full Text] [Related]
14. Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review.
Tol J; Punt CJ
Clin Ther; 2010 Mar; 32(3):437-53. PubMed ID: 20399983
[TBL] [Abstract][Full Text] [Related]
15. PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer.
Schwartzberg LS; Rivera F; Karthaus M; Fasola G; Canon JL; Hecht JR; Yu H; Oliner KS; Go WY
J Clin Oncol; 2014 Jul; 32(21):2240-7. PubMed ID: 24687833
[TBL] [Abstract][Full Text] [Related]
16. [Efficacy of cetuximab combined with chemotherapy for patients with advanced colorectal cancer and unclear K-ras status].
Guo GF; Xia LP; Qiu HJ; Xu RH; Zhang B; Jiang WQ; Zhou FF; Wang F
Zhonghua Zhong Liu Za Zhi; 2010 Oct; 32(10):777-81. PubMed ID: 21163071
[TBL] [Abstract][Full Text] [Related]
17. [A perspective: role of targeted therapy in colon cancer].
Chung HH; Jang BI
Korean J Gastroenterol; 2013 Mar; 61(3):128-35. PubMed ID: 23575231
[TBL] [Abstract][Full Text] [Related]
18. The efficacy and safety of panitumumab administered concomitantly with FOLFIRI or Irinotecan in second-line therapy for metastatic colorectal cancer: the secondary analysis from STEPP (Skin Toxicity Evaluation Protocol With Panitumumab) by KRAS status.
Mitchell EP; Piperdi B; Lacouture ME; Shearer H; Iannotti N; Pillai MV; Xu F; Yassine M
Clin Colorectal Cancer; 2011 Dec; 10(4):333-9. PubMed ID: 22000810
[TBL] [Abstract][Full Text] [Related]
19. Current therapies for advanced colorectal cancer.
Aggarwal S; Chu E
Oncology (Williston Park); 2005 Apr; 19(5):589-95. PubMed ID: 15945340
[TBL] [Abstract][Full Text] [Related]
20. Phase II trial of cetuximab plus irinotecan for oxaliplatin- and irinotecan-based chemotherapy-refractory patients with advanced and/or metastatic colorectal cancer: evaluation of efficacy and safety based on KRAS mutation status (T-CORE0801).
Soeda H; Shimodaira H; Gamoh M; Ando H; Isobe H; Suto T; Takahashi S; Kakudo Y; Amagai K; Mori T; Watanabe M; Yamaguchi T; Kato S; Ishioka C
Oncology; 2014; 87(1):7-20. PubMed ID: 24968756
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
